Puma Biotech Files 8-K, Confirms Nasdaq Listing

Ticker: PBYI · Form: 8-K · Filed: Jan 18, 2024 · CIK: 1401667

Puma Biotechnology, Inc. 8-K Filing Summary
FieldDetail
CompanyPuma Biotechnology, Inc. (PBYI)
Form Type8-K
Filed DateJan 18, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, corporate-governance, exchange-listing

TL;DR

**PBYI filed a routine 8-K, confirming its Nasdaq listing.**

AI Summary

Puma Biotechnology, Inc. filed an 8-K on January 18, 2024, primarily to disclose general information and confirm its registration on The Nasdaq Stock Market LLC (Nasdaq Global Select Market) under the trading symbol PBYI. This filing, while routine, matters to investors because it reaffirms the company's compliance with SEC regulations and its continued listing on a major exchange, which is crucial for liquidity and investor confidence in PBYI stock.

Why It Matters

This filing confirms Puma Biotechnology's ongoing compliance with SEC reporting requirements and its active listing on Nasdaq, which is fundamental for its stock's trading and visibility.

Risk Assessment

Risk Level: low — This 8-K is a standard, informational filing and does not introduce new risks or significant changes to the company's operations or financial health.

Analyst Insight

A smart investor would view this as a routine compliance filing, indicating no immediate operational or financial changes, and would continue to monitor for more substantive news regarding the company's drug development or financial performance.

Key Numbers

  • 001-35703 — Commission File Number (identifies Puma Biotechnology's registration with the SEC)
  • 77-0683487 — IRS Employer Identification No. (identifies Puma Biotechnology for tax purposes)
  • 2024-01-18 — Date of Report (the date the earliest event in the filing occurred)

Key Players & Entities

  • PUMA BIOTECHNOLOGY, INC. (company) — the registrant filing the 8-K
  • The Nasdaq Stock Market LLC (company) — the exchange where PBYI common stock is registered
  • PBYI (company) — the trading symbol for Puma Biotechnology, Inc.
  • January 18, 2024 (date) — the date of the earliest event reported in the 8-K
  • 001-35703 (dollar_amount) — the Commission File Number for Puma Biotechnology, Inc.

Forward-Looking Statements

  • Puma Biotechnology will continue to maintain its listing on The Nasdaq Stock Market LLC. (PUMA BIOTECHNOLOGY, INC.) — high confidence, target: 2025-01-18
  • The company will continue to file routine SEC disclosures as required. (PUMA BIOTECHNOLOGY, INC.) — high confidence, target: 2025-01-18

FAQ

What is the primary purpose of this 8-K filing by Puma Biotechnology, Inc.?

The primary purpose of this 8-K filing, dated January 18, 2024, is to provide current report information pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically noting Regulation FD Disclosure and Financial Statements and Exhibits, and confirming the company's registration on The Nasdaq Stock Market LLC.

On which stock exchange is Puma Biotechnology, Inc.'s Common Stock registered?

Puma Biotechnology, Inc.'s Common Stock, with a par value of $0.0001 per share, is registered on The Nasdaq Stock Market LLC (Nasdaq Global Select Market).

What is the trading symbol for Puma Biotechnology, Inc.?

The trading symbol for Puma Biotechnology, Inc. is PBYI.

What is the business address of Puma Biotechnology, Inc. as stated in the filing?

The business address of Puma Biotechnology, Inc. is 10880 Wilshire Boulevard, Suite 2150, Los Angeles, California 90024.

What is the state of incorporation for Puma Biotechnology, Inc.?

Puma Biotechnology, Inc. is incorporated in Delaware.

Filing Stats: 622 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-01-18 09:00:45

Key Financial Figures

  • $0.0001 — ch registered Common Stock, par value $0.0001 per share   PBYI   Th

Filing Documents

01

Item 7.01 Regulation FD Disclosure.   On January 18, 2024, Alan H. Auerbach, the Chairman, President, Chief Executive Officer and Secretary of Puma Biotechnology, Inc. (the "Company"), intends to make a presentation at the virtual B. Riley Securities 4 th Annual Oncology Conference: Tumor-ow's Titans – Finding Value in (Near-) Commercial Oncology Companies, and this presentation may include the information contained in Exhibit 99.1 attached to this Current Report on Form 8-K, which is incorporated herein by reference and constitutes a part of this report.   The information included under Item 7.01 in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.   

Financial Statements and Exhibits

Financial Statements and Exhibits.   (d) Exhibits.   99.1 Presentation of Puma Biotechnology, Inc., dated January 2024. 104 Cover Page Interactive Data File (formatted as inline XBRL).         SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.           PUMA BIOTECHNOLOGY, INC.       Date: January 18, 2024 By: /s/ Alan H. Auerbach     Alan H. Auerbach     Chief Executive Officer and President        

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.